Cholesterol reduction yields clinical benefits: meta-analysis including recent trials
References (116)
- et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
Lancet
(2004) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
Lancet
(2003) - et al.
Current concepts in cardiovascular pathology: The role of LDL cholesterol in plaque rupture and stabilization
Am J Med.
(1998) - et al.
PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
Lancet
(2002) - et al.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial
Lancet
(2003) - et al.
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
Lancet
(1996) - et al.
Fifteen year mortality in Coronary Drug Project patients: Longterm benefit with niacin
J Am Coll Cardiol.
(1986) - et al.
Controlled trial of clofibrate in cerebral vascular disease
Atherosclerosis
(1972) - et al.
Influence of reduction of serum lipids on prognosis of coronary heart-disease. A five year study using oestrogen
Lancet
(1961) - et al.
Effects of changes in fat, fish, and fibre intakes on death and myocar dial reinfarction: Diet and reinfarction trial (DART)
Lancet
(1989)
Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
Lancet
(1992)
Prevention of restenosis by lovastatin after successful coronary an gioplasty
Am Heart J.
(1991)
WHO clofibrate/cholesterol trial: Clarifications
Lancet
(1992)
Colestipol hydrochloride in hypercholesterolemic patients effect on serum cholesterol and mortality
J Chronic Dis.
(1978)
Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men
Lancet
(1981)
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
Am J Cardiol.
(2002)
The World Health Report: 2003; shaping the future. [WHO Web site]
(2003)
The World Health Report: 2002; reducing risks, promoting healthy life [WHO Web site]
(2002)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial
Lancet
(2003)
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes
N EngI J Med.
(2004)
Statin therapy, LDLcholesterol, C-reactive protein, and coronary artery disease
N Engl J Med.
(2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
N Engl J Med.
(2005)
Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions
Lancet
(2004)
Effect of intensive compared with moderate lipid-lowering therapy on progression of coro nary atherosclerosis: A randomized controlled trial
JAMA
(2004)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
Circulation
(2002)
Acute coronary syndromes: Biology
Lancet
(1999)
Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
Circulation
(1998)
Molecular bases of the acute coronary syndromes
Circulation
(1995)
What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?
Am J Cardiol
(1995)
Cholesterol reduction yields clinical benefit: Impact of statin trials
Circulation
(1998)
Cholesterol reduction yields clinical benefit. A new look at old data
Circulation
(1995)
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366:1358]
Lancet
(2005)
C-reactive protein levels and outcomes after statin therapy
N Engl J Med.
(2005)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004; 110:763]
Circulation
(2004)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
JAMA
(1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
N Engl J Med.
(1998)
Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: Do stopped trials contribute to overall knowledge?
Ital Heart J
(2000)
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
JAMA
(2002)
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
JAMA
(2005)
Early intensive vs a delayed conser vative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
JAMA
(2004)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial
Lancet.
(2002)
The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT LLT)
JAMA
(2002)
Effect of pravastatin-induced LDL cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease studypravastatin atherosclerosis trial (Holicos-PAT)
J Atheroscler Thromb.
(2002)
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
N Engl J Med.
(1997)
The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS)
Eur Heart J.
(1997)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
Circulation
(2000)
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
N Engl J Med.
(1999)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
Lancet
(2005)
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclero sis Intervention Study, a randomised study
Lancet
(2001)
Cited by (120)
The joint effect between fetal growth and health behaviors on the risk of cardiovascular diseases in young adulthood
2023, Annals of EpidemiologyCitation Excerpt :Studies showed high levels of oxidative stress [23] and inflammation [24] in these neonates. Alterations in fetal epigenomics [25], lipid profile [26], and gut microbiota [28] in these infants may further contribute to an increased risk of CVDs later in life. Furthermore, birth weight-for-gestational age was associated with DNA methylation at birth and in childhood [27].
Oxysterols are potential physiological regulators of ageing
2022, Ageing Research ReviewsEffects of guar gum supplementation on the lipid profile: A systematic review and meta-analysis of randomized controlled trials
2021, Nutrition, Metabolism and Cardiovascular DiseasesCardiovascular Protection by Dietary Polyphenols
2020, Comprehensive FoodomicsInvestigating cholesterol metabolism and ageing using a systems biology approach
2017, Proceedings of the Nutrition Society
Copyright © 2007 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.